Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over bioequivalence study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2026-528581-19-00treatment of diabetes
Vianex S.A.
Hormonal diseases
Czechia
19/11/2026
Phase III
Canbas Co. Ltd.
Neoplasms
Czechia, France, Germany
18/11/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Greece, Belgium, Germany, Spain, Czechia
18/11/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Greece, Spain, Germany, Portugal, Belgium, Denmark, Italy
18/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Denmark, Czechia, Lithuania, Portugal, Greece, Germany, Spain, Finland, Netherlands
18/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Digestive System Diseases
Netherlands, Belgium, Greece, Spain, Lithuania, Germany, Czechia, Italy, Portugal, Sweden
17/11/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Spain, Belgium, France, Germany, Czechia, Greece
16/11/2026
Phase III
Pulmovant Inc.
Cardiovascular Diseases
France, Netherlands, Germany, Latvia, Sweden, Portugal, Belgium, Lithuania, Czechia, Greece
16/11/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Poland, Greece, Czechia, Hungary
16/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
France, Netherlands, Belgium, Spain, Germany, Italy, Slovakia, Sweden, Czechia, Lithuania, Greece, Portugal
16/11/2026
Phase III
Calcilytix Therapeutics Inc.
Hormonal diseases
France, Italy, Spain, Czechia, Netherlands, Denmark, Germany, Hungary
16/11/2026
Phase II
Faron Pharmaceuticals Oy
Hemic and Lymphatic Diseases
Finland, France, Czechia, Poland
13/11/2026
Phase III
Daiichi Sankyo Inc.
Neoplasms
Italy, Portugal, Poland, France, Spain, Germany, Czechia
13/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Netherlands, Austria, Czechia, Belgium, Slovakia, Finland, Poland, Spain, Ireland, Sweden, Germany, Hungary, Denmark, Italy, Portugal
11/11/2026
Phase III
Institut De Recherches Internationales Servier IRIS
Cardiovascular Diseases
Bulgaria, Poland, Czechia, France, Spain, Greece, Hungary, Portugal
11/11/2026
Phase III
Merck Sharp & Dohme LLC
Eye Diseases
Portugal, Austria, Spain, Czechia, Hungary, France, Poland
11/11/2026
Phase III
Seismic Pharmaceuticals Operations LLC
Cardiovascular Diseases
Spain, Portugal, Bulgaria, Italy, Poland, Romania, Czechia, Greece
10/11/2026
Phase III
Vanda Pharmaceuticals Inc.
Digestive System Diseases
Czechia, Estonia, Bulgaria, Romania, Latvia, Poland
10/11/2026
Phase III
Novartis Pharma AG
Neoplasms
Czechia, Portugal, Germany, Austria, Poland, Belgium, Spain, Netherlands, Italy, France, Slovakia
10/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Italy, Netherlands, Poland, Belgium, Spain, France, Czechia, Bulgaria, Germany, Slovakia
09/11/2026
Phase III
Zydus Therapeutics Inc.
Digestive System Diseases
Poland, Romania, Greece, Italy, Spain, Czechia
06/11/2026
Phase III
Priovant Therapeutics Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Poland, Netherlands, France, Italy, Spain, Hungary, Germany
06/11/2026
Phase III
Hunan Mabgeek Biotech Co. Ltd.
Skin and Connective Tissue Diseases
Czechia, Spain, Poland
04/11/2026
Phase III
Nektar Therapeutics
Skin and Connective Tissue Diseases
Lithuania, Slovakia, Bulgaria, Greece, Czechia, Poland, Spain, Belgium, Germany
03/11/2026
Phase II
Antev Limited
Male Urogenital Diseases
Bulgaria, Lithuania, Poland, Czechia
03/11/2026
Phase III
Nektar Therapeutics
Immune System Diseases
Portugal, Austria, Poland, Latvia, Italy, Czechia, Germany, Hungary, Croatia
03/11/2026
Phase I
Polpharma Biologics International AG
Nervous System Diseases
Poland, Croatia, Czechia, Bulgaria
02/11/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden
30/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Czechia, Poland, Austria, Italy, Spain, Sweden, Germany, France, Netherlands, Portugal, Finland, Greece
27/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Germany, Poland
27/10/2026
Phase III
Celcuity Inc.
Neoplasms
Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain
27/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Portugal, Bulgaria, Germany, Croatia, Hungary, Czechia, Romania, Spain, Italy, Denmark, Slovakia, Greece, Poland
23/10/2026
Phase III
Astellas Pharma Global Development Inc.
Neoplasms
Poland, Romania, Spain, Belgium, Czechia, Portugal, Italy, Germany, France
23/10/2026
Phase I
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Nutritional and Metabolic Diseases
Czechia
21/10/2026
Phase I/II
SOTIO Biotech a.s.
Neoplasms
Czechia, Spain, France, Belgium
20/10/2026
Phase II
Triveni Bio Inc.
Skin and Connective Tissue Diseases
Czechia, Poland
20/10/2026
Phase III
AstraZeneca AB
Musculoskeletal Diseases
Netherlands, Belgium, Bulgaria, Romania, Italy, Germany, Austria, Spain, Portugal, Greece, Czechia, Poland, France
20/10/2026
Phase III
Newave Pharmaceutical Inc.
Hemic and Lymphatic Diseases
Poland, Germany, Spain, Czechia, Italy, France
20/10/2026
Phase II
Vensica Medical Ltd.
Female Urogenital Diseases and Pregnancy Complications
Portugal, Italy, Czechia, Poland
20/10/2026
Phase III
Genmab A/S
Neoplasms
Italy, Poland, Greece, France, Spain, Austria, Bulgaria, Germany, Hungary, Czechia, Netherlands, Belgium, Romania, Denmark
19/10/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, Germany, Spain
19/10/2026
Phase III
CSL Behring LLC
Immune System Diseases
Czechia, Denmark, France, Spain, Italy, Poland, Belgium, Germany
19/10/2026
Phase II
Foresee Pharmaceuticals USA Inc.
Respiratory Tract Diseases
Spain, Hungary, Czechia
19/10/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Poland, France, Italy, Germany, Czechia, Romania, Hungary
15/10/2026
Phase II
Sitala Bio Limited
Eye Diseases
Poland, Czechia
14/10/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Spain, Italy, Portugal, Poland, France, Netherlands, Germany, Belgium, Czechia
12/10/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Italy, Austria, Greece, Ireland, Bulgaria, Poland, Sweden, Belgium, Germany, Spain, Czechia, France, Romania, Hungary
08/10/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Italy, Czechia, Germany, Bulgaria, France, Poland
08/10/2026
Phase III
Vivus B.V., Vivus LLC
Respiratory Tract Diseases
Italy, France, Czechia, Poland, Latvia, Germany, Spain
05/10/2026
Phase II
Argenx
Not possible to specify
Spain, Poland, Czechia, Belgium, Italy
05/10/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Austria, Portugal, Slovakia, Italy, Poland, Hungary, Spain, Czechia, France, Netherlands, Germany
05/10/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Portugal, Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase II
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase III
Shenzhen Oculgen Biomedical Technology Co. Ltd.
Eye Diseases
Latvia, Poland, Czechia, Hungary
24/09/2026
Phase II
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Czechia, Italy, Poland, Bulgaria
21/09/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase II
Sanofi Vaccines US Inc.
Virus Diseases
Estonia, Spain, Germany, Czechia, Poland, Finland, Netherlands
21/09/2026
Phase II
AnaCardio AB
Cardiovascular Diseases
Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary
21/09/2026
Phase III
Celea Therapeutics Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase III
Minervax ApS
Bacterial Infections and Mycoses
Czechia, Belgium, Denmark, Spain
18/09/2026
Phase II
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia, Germany, Poland, Spain, Bulgaria
18/09/2026
Phase III
Genmab A/S
Neoplasms
Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland
18/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Greece, Czechia, Poland
18/09/2026
Phase III
Aura Biosciences Inc.
Neoplasms
Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy
17/09/2026
Phase III
Immuneering Corp.
Neoplasms
Spain, Czechia, Hungary, Belgium, Poland, Germany, France, Italy, Romania
17/09/2026
Phase III
Pharmacosmos A/S
Neoplasms
Czechia, Greece, France, Belgium, Italy, Spain, Germany
17/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Czechia, Greece, Poland
17/09/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase III
Janssen Cilag International
Neoplasms
Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain
16/09/2026
Phase III
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase II
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase II
H. Lundbeck A/S
Nervous System Diseases
Czechia, France, Spain, Poland, Italy, Germany, Sweden
15/09/2026
Phase III
Grifols Therapeutics LLC
Immune System Diseases
Italy, Poland, Czechia, France, Spain
14/09/2026
Phase II
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia, Bulgaria, Poland, Spain
10/09/2026
Phase II
Neurocrine Biosciences Inc.
Nervous System Diseases
Bulgaria, Croatia, Romania, Slovakia, Czechia
07/09/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase II
Mediwound Ltd.
Skin and Connective Tissue Diseases
Czechia, Slovakia
01/09/2026
Phase II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase II
Idorsia Pharmaceuticals Ltd.
Skin and Connective Tissue Diseases
Czechia, Poland
26/08/2026
Phase II
Itb-Med LLC
Immune system processes
Czechia, Spain, Portugal, Austria
25/08/2026
Phase I
Adamed Pharma S.A.
Not possible to specify
Czechia
25/08/2026
Phase II
Apollo Therapeutics Limited
Skin and Connective Tissue Diseases
Hungary, Czechia, Germany, Bulgaria, Poland, Spain
25/08/2026
Phase I
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
25/08/2026
Phase III
Biocodex
Nervous System Diseases
Bulgaria, France, Romania, Czechia
24/08/2026
Phase III
Revolution Medicines Inc.
Neoplasms
Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark
24/08/2026
Phase III
Laboratorios Farmaceuticos Rovi S.A.
Neoplasms
Romania, Spain, Bulgaria, Czechia, Latvia, Poland, Croatia, Slovakia
21/08/2026
Phase III
Deciphera Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland
21/08/2026
Phase III
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase II
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase I
Laboratorios Leon Farma S.A.
Female Urogenital Diseases and Pregnancy Complications
Czechia
14/08/2026
Phase II
Kinaset Therapeutics Inc.
Respiratory Tract Diseases
Czechia, Bulgaria, Romania, Hungary, Germany, Poland, Greece
14/08/2026
Phase I
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
12/08/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
10/08/2026
Phase III
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase I
An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2026-526397-17-00treatment of diabetes
Vianex S.A.
Hormonal diseases
Czechia
05/08/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Germany, Bulgaria, Czechia
04/08/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Slovakia, Poland, Czechia, Germany, Hungary, Greece, Denmark
03/08/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase I
Laboratorios Cinfa S.A.
Nervous System Diseases
Czechia
30/07/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Hungary, Czechia, Spain, Netherlands
30/07/2026
Phase III
AstraZeneca AB
Neoplasms
Denmark, Czechia, France, Germany, Hungary, Italy, Spain, Poland
29/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain, Belgium
23/07/2026
Phase III
Chemo Research S.L.
Not possible to specify
Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania
23/07/2026
Phase III
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase II
Microbial Resource Management Health
Digestive System Diseases
Czechia, Poland, Italy
16/07/2026
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy
14/07/2026
Phase I/II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy
13/07/2026
Phase III
Grifols Therapeutics LLC
Nervous System Diseases
Romania, Czechia, Poland
07/07/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal
07/07/2026
Phase III
F. Hoffmann-La Roche AG
Neoplasms
France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland
07/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain
06/07/2026
Phase I
Vipharm S.A.
Cardiovascular Diseases
Czechia
02/07/2026
Phase III
Janssen Cilag International
Neoplasms
Poland, Spain, Czechia, France, Italy, Germany, Greece
01/07/2026
Phase II
AstraZeneca AB
Respiratory Tract Diseases
Czechia, Poland, Hungary
01/07/2026
Phase III
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Phase III
Hamlet BioPharma AB
Male Urogenital Diseases
Czechia
29/06/2026
Phase III
Schneider Children's Medical Center Of Israel
Musculoskeletal Diseases
Greece, Poland, France, Czechia
23/06/2026
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Czechia, France, Spain, Italy
19/06/2026
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Musculoskeletal Diseases
France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain
15/06/2026
Phase IV
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Austria, Belgium, Czechia
15/06/2026
Phase I
Pevisal Group Farmaceutici S.r.l.
Reproductive and Urinary Physiological Phenomena
Czechia
12/06/2026
Phase II
Eli Lilly & Co.
Digestive System Diseases
Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania
10/06/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Norway, Czechia, Portugal, Austria, Poland, France, Spain
08/06/2026
Phase III
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway
08/06/2026
Phase II
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase III
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I
Laboratorios Cinfa S.A.
Nervous System Diseases
Czechia
04/06/2026
Phase II
Fakultni Nemocnice Kralovske Vinohrady
Otorhinolaryngologic Diseases
Czechia
02/06/2026
Phase I
Adamed Pharma S.A.
Cardiovascular Diseases
Czechia
02/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase I
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524219-35-00treatment of myasthenia gravis
Vianex S.A.
Musculoskeletal Diseases
Czechia
02/06/2026
Phase III
Innocare Pharma Inc.
Neoplasms
Poland, France, Czechia, Spain, Romania
01/06/2026
Phase II
Centre Hospitalier De Versailles
Hemic and Lymphatic Diseases
Germany, France, Czechia, Netherlands, Spain
29/05/2026
Phase III
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase IV
Fakultni Nemocnice Brno
Female Urogenital Diseases and Pregnancy Complications
Czechia
28/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase II
Maplight Therapeutics Inc.
Mental Disorders
Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary
27/05/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase I
MIDAS Pharma GmbH
Anesthesia and Analgesia
Czechia
26/05/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
22/05/2026
Phase II
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands
21/05/2026
Phase III
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, France, Poland, Bulgaria, Czechia
20/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Romania, Denmark
20/05/2026
Phase II
Elevara Medicines Limited
Immune System Diseases
Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain
19/05/2026
Phase III
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase III
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy
13/05/2026
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Germany, France, Norway
12/05/2026
Phase III
Generate Biomedicines Inc.
Respiratory Tract Diseases
Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia
12/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase III
A. Menarini International Licensing S.A.
Hemic and Lymphatic Diseases
Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany
11/05/2026
Phase III
Octapharma Pharmazeutika Produktionsgesellschaft mbH
Immune System Diseases
Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy
11/05/2026
Phase III
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
05/05/2026
Phase III
Dompe' Farmaceutici S.p.A.
Eye Diseases
Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France
05/05/2026
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Bulgaria, Hungary, Spain, Germany, Czechia, Poland
05/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase II
Novartis Pharma AG
Eye Diseases
Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France
04/05/2026
Phase III
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Hungary, Poland, Bulgaria, Germany, Czechia, Spain
04/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain
04/05/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase I
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase III
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase III
Cinclus Pharma Holding AB (publ)
Digestive System Diseases
Hungary, Germany, Romania, Bulgaria, Czechia, Poland
28/04/2026
Phase I
Bioinova a.s.
Eye Diseases
Czechia
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden
28/04/2026
Phase III
Epygenix Therapeutics Inc.
Nervous System Diseases
Italy, Spain, Hungary, Romania, Czechia, Poland
28/04/2026
Phase III
Exciva GmbH
Nervous System Diseases
Italy, Slovakia, Spain, Poland, Czechia, Germany
28/04/2026
Phase II
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain
27/04/2026
Phase II
AstraZeneca AB
Neoplasms
Italy, Austria, Spain, Ireland, Czechia, Poland
27/04/2026
Phase I/II
Novartis Pharma AG
Neoplasms
Italy, Spain, Germany, Netherlands, France, Denmark, Czechia
27/04/2026
Phase I
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
24/04/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Romania, Belgium, Czechia
21/04/2026
Phase I
Lakefront Biotherapeutics West LLC
Immune System Diseases
Czechia
21/04/2026
Phase III
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
Eli Lilly & Co.
Neoplasms
Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain
20/04/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase I/II
Novartis Pharma AG
Neoplasms
Italy, Germany, France, Czechia, Denmark, Spain
16/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland
16/04/2026
Phase III
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase II
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase III
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase III
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria
02/04/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Denmark, Belgium, Germany, Czechia
02/04/2026
Phase III
Alfasigma S.p.A.
Immune System Diseases
France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy
01/04/2026
Phase II
Bluefin Biomedicine Inc.
Immune System Diseases
Spain, Germany, Czechia, Poland, Bulgaria
31/03/2026
Phase III
NewAmsterdam Pharma B.V.
Cardiovascular Diseases
Czechia, Slovakia, Netherlands
31/03/2026
Phase IV
Fakultni Nemocnice V Motole
Nervous System Diseases
Czechia, Poland
30/03/2026
Phase III
Eyepoint Inc.
Eye Diseases
Hungary, Czechia, Germany
30/03/2026
Phase I
Orion Corporation
Nervous System Diseases
Czechia
27/03/2026
Phase III
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Germany, Spain, Poland, Czechia, Slovakia
24/03/2026
Phase III
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase II
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Phase II
Fakultni Nemocnice Ostrava
Cardiovascular Diseases
Czechia
19/03/2026
Phase IV
Institute For Clinical And Experimental Medicine
Digestive System Diseases
Czechia
18/03/2026
Phase II
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase II
Masarykova Univerzita
Nervous System Diseases
Czechia
17/03/2026
Phase II
Novartis Pharma AG
Immune System Diseases
Czechia, Germany, Spain, Italy, Poland
17/03/2026
Phase I/II
Universitaetsklinikum Heidelberg AöR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
UCB Biopharma
Immune System Diseases
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria
16/03/2026
Phase III
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase I
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Nutritional and Metabolic Diseases
Czechia
11/03/2026
Phase II
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Slovakia, Czechia, Romania, Latvia, Germany, Hungary, Bulgaria, Poland
11/03/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase II
UCB Biopharma
Skin and Connective Tissue Diseases
Bulgaria, Czechia, Germany, Poland, Hungary
09/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase III
Alvotech Swiss AG
Eye Diseases
Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria
06/03/2026
Phase I
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.
2026-525256-29-00Comparative bioavailability study under fasting conditions
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
04/03/2026
Phase III
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
Draig Therapeutics Limited
Mental Disorders
Czechia, Bulgaria, Poland
24/02/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase I
Vianex S.A.
Cardiovascular Diseases
Czechia
18/02/2026
Phase III
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase II
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase III
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase III
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase I
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
12/02/2026
Phase III
Summit Therapeutics Inc.
Neoplasms
Belgium, Italy, Spain, Germany, France, Poland, Czechia, Hungary, Ireland
12/02/2026
Phase III
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Germany, Czechia, Hungary, Spain, France
10/02/2026
Phase III
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase III
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
Biogen Idec Research Limited
Immune System Diseases
Germany, Austria, Spain, Czechia, France
09/02/2026
Phase IV
Masarykova Univerzita
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Czechia
09/02/2026
Phase III
Mb Pharma Group s.r.o.
Skin and Connective Tissue Diseases
Czechia
09/02/2026
Phase I
Oxytone Bioscience B.V.
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/02/2026
Phase I
Faes Farma S.A.
Not possible to specify
Czechia
06/02/2026
Phase III
Mirum Pharmaceuticals Inc.
Virus Diseases
Czechia, Austria, Spain, Romania, Germany, Italy, France
03/02/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Finland, Germany, Italy, France, Sweden, Poland, Spain, Belgium, Czechia, Netherlands, Portugal, Norway
03/02/2026
Phase III
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany, Slovenia
29/01/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Czechia, Germany, Hungary, France, Spain
27/01/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase III
Xenon Pharmaceuticals Inc.
Mental Disorders
Spain, Czechia, Slovakia, Romania, Poland, Finland, Germany
26/01/2026
Phase III
Eli Lilly & Co.
Female Urogenital Diseases and Pregnancy Complications
Romania, Czechia, Poland
26/01/2026
Phase III
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Czechia, France, Belgium, Denmark
19/01/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase III
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase II
Novartis Pharma AG
Skin and Connective Tissue Diseases
France, Germany, Poland, Czechia, Bulgaria
14/01/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy
14/01/2026
Phase II
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase II
Kymera Therapeutics Inc.
Skin and Connective Tissue Diseases
Czechia, Germany, Poland
13/01/2026
Phase I
ReproNovo ApS
Female Urogenital Diseases and Pregnancy Complications
Czechia
09/01/2026
Phase I/II
35Pharma Inc.
Cardiovascular Diseases
Hungary, Spain, Poland, Germany, Czechia
23/12/2025
Phase II
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece
22/12/2025
Phase III
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase I
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.
2025-524218-27-00treatment of myasthenia gravis
Vianex S.A.
Musculoskeletal Diseases
Czechia
19/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Male Urogenital Diseases
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase III
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase III
Vertex Pharmaceuticals Inc.
Immune System Diseases
Hungary, Ireland, Czechia, Italy, Spain, Germany, Netherlands
12/12/2025
Phase III
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase II
Triveni Bio Inc.
Skin and Connective Tissue Diseases
Poland, Bulgaria, Czechia, Hungary
09/12/2025
Phase I
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
09/12/2025
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia, Sweden
09/12/2025
Phase III
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Belgium, Slovenia
09/12/2025
Phase II
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase II
Bayer AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, Poland, Czechia, Germany, Portugal, France
05/12/2025
Phase III
Bayer AG
Cardiovascular Diseases
Czechia, Germany, Greece, Italy, Finland, Bulgaria, Belgium, Poland, Austria, Portugal, Spain, Hungary, Sweden
05/12/2025
Phase III
(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)
2024-519829-38-00Heart failure due to systemic left ventricular systolic dys…
Bayer AG
Cardiovascular Diseases
Czechia, Poland, Portugal, Austria, Finland, Greece, Bulgaria, Sweden, Spain, Italy, Belgium, Hungary, Germany
05/12/2025
Phase III
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase III
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase II
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase I
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524217-89-00treatment of myasthenia gravis
Vianex S.A.
Musculoskeletal Diseases
Czechia
01/12/2025
Phase III
Adamed Pharma S.A.
Bacterial Infections and Mycoses
Italy, Czechia, Poland, Slovakia
01/12/2025
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase II
Spyre Therapeutics Inc.
Immune System Diseases
Czechia, Poland, Spain, Bulgaria
25/11/2025
Phase III
Arcus Biosciences Inc.
Neoplasms
Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary
24/11/2025
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Czechia, Greece, Latvia, Austria, Germany, Bulgaria, Romania, Italy
24/11/2025
Phase I
Institut De Recherches Internationales Servier IRIS
Neoplasms
Czechia, Spain
24/11/2025
Phase II
Gesynta Pharma AB
Female Urogenital Diseases and Pregnancy Complications
Italy, Hungary, Poland, Czechia, Bulgaria, Romania
21/11/2025
Phase III
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia, Spain
17/11/2025
Phase III
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia
10/11/2025
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase III
BeOne Medicines AG
Neoplasms
Spain, France, Austria, Italy, Poland, Czechia
10/11/2025
Phase II
Seaport Therapeutics Inc.
Mental Disorders
Bulgaria, Czechia, Germany, Poland, Hungary, Slovakia, Romania
06/11/2025
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Bulgaria, Spain, Netherlands, Italy, Poland, Greece, Germany, France, Czechia, Croatia, Norway, Sweden
04/11/2025
Phase III
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
Neoplasms
Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium
04/11/2025
Phase I/II
Bayer AG
Neoplasms
Belgium, Sweden, Denmark, Italy, Spain, Netherlands, Czechia
04/11/2025
Phase III
Otsuka Pharmaceutical Development & Commercialization Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Czechia, Italy, Spain, Netherlands, Poland, France, Germany
03/11/2025
Phase III
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Italy, France, Bulgaria
03/11/2025
Phase I/II
Glaxosmithkline Research & Development Limited
Neoplasms
Estonia, Czechia, Spain, Romania, Italy, Denmark, Belgium, Greece
03/11/2025
Phase II
Bluefin Biomedicine Inc.
Immune System Diseases
Poland, Bulgaria, Germany, Czechia, Spain
31/10/2025
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Romania, Croatia, Slovakia, Hungary
29/10/2025
Phase II
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Bulgaria, Czechia, Italy, France
29/10/2025
Phase II
Maplight Therapeutics Inc.
Nervous System Diseases
France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland
27/10/2025
Phase III
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain, Norway
24/10/2025
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Poland, Hungary, Italy, France, Czechia
22/10/2025
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France
22/10/2025
Phase II
Phenonet Inc.
Nervous System Diseases
Germany, Czechia, Poland, Spain
21/10/2025
Phase II
Ngm Biopharmaceuticals Inc.
Nutritional and Metabolic Diseases
Czechia, Slovakia, Poland, Hungary, Bulgaria
21/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Croatia, Romania, France, Spain, Italy, Greece, Czechia, Bulgaria, Poland, Portugal, Hungary
21/10/2025